• The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing interval
  • Commercial availability expected during early part of Q2 2026
  • Rare Pediatric Disease Priority Review Voucher granted in connection with approval

Ascendis Pharma A/S has announced that the U.S. Food & Drug Administration (FDA) has granted an accelerated approval for YUVIWEL® (navepegritide), a once-weekly treatment designed to increase linear growth in children aged two years and older with achondroplasia and open growth plates. The approval marks a significant milestone in rare disease treatment and pediatric medical innovation, expanding therapeutic options for patients living with this genetic skeletal condition.

YUVIWEL is the first and only once-weekly therapy indicated for children with achondroplasia and the only treatment designed to provide continuous systemic exposure to C-type natriuretic peptide (CNP) over a weekly dosing interval. Developed as TransCon® CNP, the therapy is engineered to counteract overactive FGFR3 signaling, the underlying molecular pathway responsible for impaired bone growth in achondroplasia.

Health Technology Insights:  https://healthtechnologyinsights.com/seattle-childrens-chooses-abridge-for-pediatric-care-needs/ 

Achondroplasia is a rare genetic disorder characterized by disproportionate short stature and associated risks, including neurological, muscular, and cardiorespiratory complications. The FDA’s Accelerated Approval Program granted approval based on improvements in annualized growth velocity (AGV) observed across three randomized, double-blind, placebo-controlled clinical trials. Continued approval may depend on confirmation of long-term clinical benefits in subsequent studies.

Carlos A. Bacino, MD, FACMG, Professor of Molecular and Human Genetics at Baylor College of Medicine and Texas Children’s Hospital, described the approval as a meaningful advancement for patients and clinicians. He noted that having a once-weekly treatment option supported by strong efficacy and safety data allows physicians to tailor care plans to the unique needs and goals of children and their families.

Jan Mikkelsen, President and Chief Executive Officer of Ascendis Pharma, emphasized the company’s commitment to patient-centered innovation. “We’re confident in YUVIWEL’s potential to transform the treatment landscape for achondroplasia,” he stated, highlighting the collaboration between researchers, clinicians, and advocacy groups that contributed to this milestone. The FDA also issued a Rare Pediatric Disease Priority Review Voucher (PRV) alongside the approval, encouraging continued development of therapies for rare pediatric conditions.

From a healthcare systems perspective, the introduction of YUVIWEL reinforces the importance of precision medicine, data-driven clinical trials, and patient-focused drug development. As AI in healthcare continues to support clinical research analytics and real-world evidence generation, rare disease therapeutics are increasingly benefiting from more targeted and efficient development pathways.

Ascendis Pharma expects YUVIWEL to become available through prescribing physicians in the United States in early Q2 2026. The company will provide patient support services through its Ascendis Signature Access Program (A.S.A.P.), offering treatment navigation assistance and financial support options for eligible families.

With this approval, YUVIWEL introduces a new once-weekly medical treatment paradigm for children with achondroplasia, potentially reshaping standards of care while reinforcing innovation in pediatric rare disease management.

Health Technology Insights: https://healthtechnologyinsights.com/connecticut-childrens-care-network-innovaccer-partner-to-boost-population-health/ 

To share our interviews, please write to our HealthTech Media Room at info@intentamplify.com